Surge in M&As Driven by Patent Expirations

Why It Matters

The wave of acquisitions helps pharma replace expiring blockbusters, preserving revenue streams and reshaping the competitive landscape as patent cliffs approach.

Key Takeaways

• EY reports 81% M&A investment jump to $240 B in 2024
• Acquisition premiums fell 40% in 2025, indicating disciplined value creation
• Big pharma buying biotech pipelines to offset looming patent‑cliff revenue losses
• Merck, Pfizer, J&J each spent $10‑15 B on recent strategic acquisitions
• Analysts expect 2026 to rank as second most active M&A year

Pulse Analysis

The latest surge in healthcare M&A reflects a strategic response to an unprecedented wave of patent expirations. EY’s data shows deal value leapt 81% to $240 billion in 2024, while the first quarter of 2025 maintained a robust pipeline of 130 transactions. At the same time, acquisition premiums have shrunk by 40% since their 2020‑2024 peak, signaling that buyers are prioritizing long‑term pipeline sustainability over short‑term financial engineering. This disciplined shift is driven by the need to replace revenue streams that will vanish as blockbuster patents run out.

Big pharmaceutical firms are leading the charge, using multi‑billion‑dollar purchases to shore up future growth. Merck’s $6.7 billion acquisition of Terns Pharmaceuticals and its $10 billion buy of Verona target the imminent loss of Keytruda’s exclusivity in 2028. Pfizer’s $10 billion deal for Metsera aims to offset the upcoming expiry of Eliquis and two cancer blockbusters, while Johnson & Johnson’s $14.6 billion purchase of Intra‑Cellular Therapies adds a novel bipolar‑depression drug to its portfolio. Across the sector, firms are also gravitating toward AI‑enabled candidates, rewarding companies that have integrated machine‑learning platforms with higher multiples.

For investors and industry observers, the M&A boom signals both opportunity and risk. Companies that successfully integrate acquired assets can sustain earnings and maintain market share, but the rapid pace of deals raises antitrust scrutiny and integration challenges. Moreover, the focus on late‑stage pipelines may crowd out early‑stage innovation, potentially slowing the emergence of breakthrough therapies. As 2026 approaches, stakeholders should monitor deal volumes, premium trends, and regulatory responses to gauge whether the current consolidation wave will stabilize the sector or trigger a new cycle of competitive disruption.